摘要
目的观察泊马度胺联合硼替佐米和地塞米松(PVD)方案治疗复发难治多发性骨髓瘤(RRMM)的临床疗效。方法以蚌埠医科大学第一附属医院2021年5月~2024年5月期间收治的78例RRMM患者为研究对象,依照随机数字表法进行完全随机化分组,分为RVD组(n=39)和PVD组(n=39)。RVD组采用硼替佐米联合来那度胺和地塞米松(RVD)方案治疗,PVD组采用PVD方案治疗。比较两组临床疗效,比较治疗前、治疗后两组骨髓瘤相关指标以及肿瘤指标变化,统计两组治疗期间不良反应发生率。结果治疗4个疗程后,PVD组总缓解率高于RVD组(P<0.05);两组M蛋白、β_(2)微球蛋白、肿瘤坏死因子α、白细胞介素6、血管内皮生长因子水平、浆细胞数量占比均较治疗前降低(P<0.05),且PVD组明显低于RVD组(P<0.05)。治疗期间,两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论PVD方案治疗RRMM疗效显著,可有效控制患者的病情进展,改善肿瘤相关指标,且不良反应少,具有较高的临床应用价值。
Objective To observe the clinical efficacy of pomalidomide combined with bortezomib and dexamethasone(PVD)regimen in the treatment of relapsed and refractory multiple myeloma(RRMM).Methods A total of 78 patients with RRMM admitted to the First Affiliated Hospital of Bengbu Medical University from May 2021 to May 2024 were selected as the research subjects.They were completely randomized grouped according to the random number table method and divided into the RVD group(n=39)and the PVD group(n=39).The RVD group was treated with the bortezomib combined with lenalidomide and dexamethasone(RVD),while the PVD group was treated with the PVD regimen.The clinical efficacy and myeloma-related indicators and tumor indicators changes before and after treatment were compared between the two groups,and the incidence rates of adverse reactions during treatment were counted.Results After 4 courses of treatment,the total remission rate in PVD group was higher than that in RVD group(P<0.05).The levels of M protein,β_(2) microglobulin,tumor necrosis factor-α,interleukin-6 and vascular endothelial growth factor and the proportion of plasma cell count in the two groups were reduced compared with those before treatment(P<0.05),and the levels and proportion were significantly lower in PVD group than those in RVD group(P<0.05).During the treatment period,there was no significant differences in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion PVD regimen has significant efficacy in the treatment of RRMM,and it can effectively control the disease progression and improve the tumor-related indicators,and it has few adverse reactions and high clinical application value.
作者
刘林
谢志滨
李佳佳
LIU Lin;XIE Zhibin;LI Jiajia(Department of Hematology,The First Affiliated Hospital of Bengbu Medical University,Bengbu 233003,China)
出处
《医师在线》
2025年第6期43-46,共4页
Journal of Doctors Online
基金
安徽省高等学校科学研究项目(自然科学类)(2023AH052011)。
